摘要
目的探究巴戟天多糖对骨质疏松模型大鼠5-HT、VEGF与体内矿物质含量影响。方法健康清洁级雄性SD大鼠90只,随机选取15只为正常对照组,其余大鼠进行骨质疏松模型复制。模型复制成功后根据不同处理方式分为模型对照组组、巴戟天高剂量组、巴戟天中剂量组、巴戟天低剂量组及阳性药组。干预4周后比较各组大鼠骨密度、5-HT、VEGF及机体矿物质水平。结果与正常对照组比较,模型对照组与低剂量组BMD较低,提示骨质疏松仍然存在;与阳性药组比较,中剂量与高剂量BMD值较高(P<0.05)。与模型对照组比较,阳性药组、高剂量组与中剂量组5-HT水平较高,与阳性药组比较,中剂量组与高剂量组5-HT水平较高(P<0.05);与模型组比较,阳性药组、中剂量组与高剂量组VEGF水平较高,与阳性药组比较,中剂量组与高剂量组VEGF水平较高(P<0.05);与模型对照组比较,阳性药组、中剂量组与高剂量组血清P含量较高,与阳性药比较,中剂量组与高剂量组含量较高(P<0.05)。结论巴戟天多糖能升高骨质疏松模型大鼠5-HT、VEGF的含量,改善血清P水平,对临床有指导意义。
Objective To explore effect of 5-HT,VEGF and mineral content in osteoporosis rat by Morinda officinalis.Methods 90 SPF male SD rats were selected, 15 rats were randomly selected as the normal control group, the rest were to establish the model of osteoporosis.When the model was established successfully according to the different treatment methods were divided into control group, model group, positive medicine group, low, middle and high does group.Bone mineral density, 5-HT, VEGF and the levels of the mineral were compared after 4 weeks treatment.Results Compared with the normal control group, BMD of model control group and low dose group was lower, Compared with the positive drug group, BMD of middle dose and high dose was higher （ P〈0.05 ）.Compared with model group,5-HT level of positive medicine group, high dose group and middle dose group was higher, compared with positive drug group, 5-HTP of middle dose group and high dose group was higher （ P 〈0.05 ）.Compared with model group, positive drug group, VEGF levels of middle dose group and high dose group were higher（P 〈0.05）, compared with positive drug group, VEGF of middle dose group and high dose group were higher（P〈0.05）, compared with model control group, positive drug group, serum P content of middle dose group was higher, compared with positive drug, serum P content of high dose group and high dose group was less.Conclusion Morindae Officinalis can increase 5-HT, VEGF in a rat model of osteoporosis, improve the level of serum P, has the guiding sense to the clinical.
出处
《中国生化药物杂志》
CAS
2015年第4期59-62,共4页
Chinese Journal of Biochemical Pharmaceutics
